Literature DB >> 21717982

Metastases of the pelvis: does resection improve survival?

Pietro Ruggieri1, Andreas F Mavrogenis, Andrea Angelini, Mario Mercuri.   

Abstract

Limited data are available to compare the outcome of wide en bloc resection and curettage for pelvic metastases. Previous studies have reported that curettage is associated with high mortality and decreased survival compared to wide resection and have justified consideration of a radical surgical approach to achieve pain palliation and tumor control. In this study, we aimed to evaluate the role of curettage/marginal resection compared to wide en bloc resection for patients with pelvic metastases. The hypothesis was that wide resection does not improve survival even in patients with solitary pelvic metastases.Between 1985 and 2009, twenty-one patients with pelvic metastases were treated with wide resection (12 patients) and curettage/marginal resection (9 patients) and adjuvants. Sixteen patients had solitary pelvic metastases. At a mean of 28 months (range, 2-152 months), we found no difference in survival to death or local recurrence with wide en bloc resection compared to curettage or marginal resection, even in patients with solitary pelvic metastases. The overall survival to death and local recurrence was 30% and 47% at 60 months, respectively. Survival to death of patients treated with wide resection was 18% at 60 months compared to 62% at 60 months of patients treated with curettage/marginal resection; no difference in survival to death between wide resection and curettage/marginal resection was observed even in patients with solitary pelvic metastases. Survival to local recurrence of patients treated with wide en bloc resection was 67% at 36 months compared to 26% at 36 months of patients treated with curettage/marginal resection; this was also not statistically significant. One patient treated with wide resection for a solitary pelvic metastasis had a postoperative complication. Copyright 2011, SLACK Incorporated.

Entities:  

Mesh:

Year:  2011        PMID: 21717982     DOI: 10.3928/01477447-20110526-07

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  8 in total

1.  Computer-aided designed, three dimensional-printed hemipelvic prosthesis for peri-acetabular malignant bone tumour.

Authors:  Baichuan Wang; Yongqiang Hao; Feifei Pu; Wenbo Jiang; Zengwu Shao
Journal:  Int Orthop       Date:  2017-09-27       Impact factor: 3.075

Review 2.  Treatment for long bone metastases based on a systematic literature review.

Authors:  Costantino Errani; Andreas F Mavrogenis; Luca Cevolani; Silvia Spinelli; Andrea Piccioli; Giulio Maccauro; Nicola Baldini; Davide Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-09-20

3.  Outcome after Surgery for Metastases to the Pelvic Bone: A Single Institutional Experience.

Authors:  Chandra Kumar Krishnan; Ilkyu Han; Han-Soo Kim
Journal:  Clin Orthop Surg       Date:  2017-02-13

4.  Oncological, surgical and functional results of the treatment of patients after hemipelvectomy due to metastases.

Authors:  Grzegorz Guzik
Journal:  BMC Musculoskelet Disord       Date:  2018-02-20       Impact factor: 2.362

5.  Clinical features and outcomes of metastatic bone tumors of the pelvis.

Authors:  Qing Yang; Nong Chen; Wenqin Fu
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

6.  Biological reconstruction following the resection of malignant bone tumors of the pelvis.

Authors:  Frank Traub; Dimosthenis Andreou; Maya Niethard; Carmen Tiedke; Mathias Werner; Per-Ulf Tunn
Journal:  Sarcoma       Date:  2013-04-03

7.  Treatment of metastatic lesions localized in the acetabulum.

Authors:  Grzegorz Guzik
Journal:  J Orthop Surg Res       Date:  2016-04-28       Impact factor: 2.359

8.  Improving functional outcome and quality of life for patients with metastatic lesion of acetabulum undergoing cement augmentation.

Authors:  Taiqiang Yan; Zhiqing Zhao; Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Sen Dong
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.